Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial - Concepedia

Concepedia

Publication | Closed Access

Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial

311

Citations

24

References

2003

Year

Joseph I. Clark, Michael B. Atkins, Walter J. Urba, Steven Creech, Robert A. Figlin, Janice P. Dutcher, Larry Flaherty, Jeffrey A. Sosman, Theodore F. Logan, R. L. White,

Journal of Clinical Oncology

Abstract

One course of high-dose bolus IL-2, though feasible, did not produce the ambitious clinically meaningful benefit anticipated when administered postoperatively to patients with resected high-risk RCC.

References

	Year	Citations

Page 1